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ABSTRACT: Phytochemical investigation of Premna odorata Blanco, Lamiaceae, 
leaves afforded the new acylated iridoid glycosides 1-3, the new acylated 
rhamnopyranoses 9 and 10, in addition to ten known compounds. The structures of 
the new compounds were confirmed using extensive 1D and 2D NMR analyses. 
Molecular modeling study suggested the potential the acylated rhamnopyranoses to 
bind at the c-Met kinase domain. Cell free Z’-LYTE assay testing revealed the good 
c-Met phosphorylation inhibitory activity of 9, followed by 8, and 10, with IC50 
values of 2.5, 6.9 and 12.7 µM, respectively. The MTT cell proliferation assay testing 
against the human c-Met-expressing highly invasive MDA-MB-23 suggested 
compound 9 as the most active with IC50 value of 13.3 µM. Testing of compound 9 
against multiple phenotypic breast cancer cell lines including MCF-7, BT-474 cells, 
and MDA-MB-468 proved enhanced activity against the highly c-Met expressing 
triple-negative breast cancer cell lines. Acylated rhmnopyranoses are potential novel 






















 Premna odorata Blanco, Lamiaceae, popularly known as “fragrant Premna” is a 
small tree native to temperate and tropical Asia, including the Philippines, and 
cultivated in different global locations.1 In the Philippines; a decoction of the leaves 
was considered as diuretic, carminative and febrifuge; and used for vaginal irrigation; 
coughs; beri-beri; abdominal pains and dysentery.1,2 The saturated linear fatty acid 
ester 1-heneicosyl formate was identified as the most potent antituberculosis 
ingredient of the leaves of P. odorata, with MIC of 8 µg/mL.1 Generally; P. odorata 
is considered among the top plant sources of acylated iridoid glycosides and 
rhmnopyranoses.3-5 P. odorata iridoids exhibited a wide range of pharmacological 
activities as antimutagenic, antitumor, antiviral and anti-inflammatory.1,2,6,7  
Breast cancer is the most commonly diagnosed cancer in women, with >40,000 
expected women deaths in 2017.8 The triple negative breast cancer (TNBC) lacks 
positive staining for the estrogen receptor, progesterone receptor (PR) and human 
epidermal growth factor 2, therefore, TNBC is resistant to the selective effective 
regimens targeting these receptors like HER2-directed and endocrine therapies.9  
c-Met is an RTK proto-oncogene, which triggers activation of several critical 
downstream signaling pathways.10-12 c-Met dysregulation correlates with aggressive 
proliferation, invasive character, and pathological motility, especially in TNBC.10-12 
Met amplification also correlates with escape from the anticancer effects of EGFR 
inhibitors and cetuximab.11,12 More than 240 small-molecule c-Met inhibitors are 
currently in different clinical trial phases, with potential to delay the progression of 
several Met-dependent malignancies.10-12 Crizotinib (Xalkori) is a dual Met and ALK 
inhibitor approved by FDA for ALK-driven lung cancer.10-12 Cabozantinib (Cometriq) 
was approved by FDA in 2012 for medullary thyroid cancer.10,11 Validated efficacies 
of these marketed agents, as well as of promising ones still undergoing clinical trials, 
validates c-Met as a molecular target in cancer therapy. 
Few c-Met inhibitory natural products were identified.13 The current study 
describes the five new natural products from P. odorata and the discovery of its 
acylated rhmnopyranoses as a novel c-Met inhibitory class with activities against a 
panel of c-Met-dependent human breast cancer cell lines.  
 
RESULTS AND DISCUSSION 
Phytochemical Investigation of P. odorata. The ethanolic P. odorata leaf extract 
afforded the new acylated iridoid glycosides 1-3 and the acylated rhamnopyranoses 9 
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and 10, along with the known premnosides E (4),14 G (5), B (6), and C (7).3 In 
addition, 6-O-α-L-(4”-O-p-methoxycinnamoyl) rhamnopyranosylcatalpol (8),4 
luteolin (11),15 diosmetin (12),2 apigenin (13),15 vitexin (14),16  and verbascoside 
(15)17 were also identified.  
The HRESIMS data for compound 1 showed an adduct molecular ion peak at m/z 
801.2621 [M+H]+, consistent with the molecular formula C39H44O18 and suggesting 
eighteen degrees of unsaturation. The 1H and 13C NMR data (Table 1), along with the 
HSQC experiment suggested six characteristic resonances for β-D-glucopyranose, six 
resonances for disubstituated α-L-rhamnopyranose and eighteen resonances 
attribuated to two trans-p-coumaric acid moieties. The remaining nine resonances 
perfectly matched a catalpol iridoid core with C-1-O-β-D-glucopyranose and 6-O-α-
L-rhamnopyranose substitution.3 The 3J-HMBC correlations of the proton H-3'' (δH 
5.18) with the quaternary carbonyl carbon C-9''' (δC 167.6) and the correlation of the 
proton H-4''
 
(δH 5.11) with the carbonyl carbon C-9'''' (δC 167.4) confrmed the location 
of  the two trans-p-coumaric moieties at carbons C-3'' and C-4'' of the 6-O-α-L-
rhamnopyranosyl moiety. Compound 1 was compared to the known related positional 
isomer premnoside E (4)14 in which the trans-p-coumaric acid moieties were attached 
at C-2'' and C-3''. The 13C NMR chemical shift of carbons C-1'' and C-4'' were 
significantly downfield shifted, ∆δC +2.5 and +5.1, respectively, while carbons C-2'', 
C-5'' and C-6 were upfield shifted by ∆δC -4.9, -1.0 and -0.5, respectively, in 
compound 1 compared to compound 4, confirming its C-4'' trans-p-coumaroyl 
substitution. Accordingly, 1 was identified as 6-O-α-L-(3'',4''-di-O-trans-p-
coumaroyl) rhamnopyranosylcatalpol, which was given the trivial name premnoside 
F. 
The HRESIMS analysis of compound 2 showed a molecular ion peak at m/z 
851.2758 [M+Na]+, suggesting a molecular formula of C41H48O18 and 28 mass units 
larger than premnoside F (1). The 1H NMR spectrum for 2 was quite similar to 1, with 
an additional oxygenated singlet (δH 3.85, 6H) assigned as C-10''' and C-10'''' methoxy 
groups. The NMR data of compound 2 (Table 1) confirmed the C-3'' and C-4'' p-
methoxycinnamoyl moieties, instead of the trans-p-coumaroyl moieties of 1. Similar 
to the comparison of premnosides E and F, the NMR data of 2 confirmed its distinct 
substitution relative to the related known positional isomer premnoside G (5).3 Thus, 
compound 2 identified as 6-O-α-L-(3'',4''-di-O-trans-p-methoxycinnamoyl)- 
rhamnopyranosylcatalpol; to which it was given the trivial name premnoside H.  
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The HRESIMS data of compound 3 proved a molecular formula of C39H44O19 
by showing a molecular ion peak at m/z 817.2553, [M+H]+. The mass of 3 was 16 
Daltons higher than the mass of 1. The 1H NMR data of 3 (Table 1) showed 
characteristic resonances for a trans-caffeic acid instead of a trans-p-coumaric moiety 
in 1. The 1H-1H COSY and HMBC data of 3 (Figure 1) suggested the location of the 
trans-p-coumaric and trans-caffeoyl moieties at C-3'' (δC 72.9) and C-4'' (δC 73.9), 
respectively. The proton H-3'' (δH 5.18) showed a 3J-HMBC correlation with the 
quaternary carbonyl carbon C-9''' while the proton H-4''
 
(δC 5.11) showed a 3J-HMBC 
correlation with the carbonyl carbon C-9''''. The 13C NMR data of 3 clearly 
distinguished its identity as it compared to the related positional isomer premnoside B 
(6).3  Hence, compound 3 was identified as 6-O-α-L-(3''-O-trans-p-coumaroyl-4''-O-
trans-caffeoyl)-rhamnopyranosylcatalpol, which was named premnoside I. 
Analysis of the HRESIMS, 1D and 2D NMR data of compounds 9 and 10 
indicated their acylated rhamanopyranosyl identity, with trans-p-coumaroyl and 
trans-caffeoyl disubstitution.14  The HRESIMS data of 9 showed an adduct molecular 
ions at m/z 473.1426 [M+H]+, which suggested the molecular formula of C24H24O10 
and thirteen degrees of unsaturation. Analysis of the 1H and 13C NMR data (Table 2), 
HSQC, HMBC, and 1H-1H COSY results (Figure 1) aided the assignment of the 
trans-p-coumaroyl moiety at C-1 (δC 91.9) and  the trans-caffoyl moiety at C-2 (δC 
73.7). The anomeric proton H-1 (δH 5.19) showed a 3J-HMBC correlation with the 
trans-p-coumaroyl carbonyl carbon C-9', confirming the C-1 trans-p-coumaroyl 
esterification. Similarly, proton H-2 (δH 5.19) showed a 3J-HMBC correlation with the 
trans-caffeoyl carbonyl carbon, confirming the C-2 trans-caffeoyl esterification. 
Accordingly compound 9 was identified as 1-O-trans-p-hydroxycinnamoyl-2-O-
trans-caffeoyl-α-L-rhamnopyranose   
The HRESIMS and molecular formula of compound 10 was identical to that 
of compound 9. Their 1H and 13C NMR data were also closely similar (Table 2). The 
HSQC, HMBC and 1H-1H COSY experiments confirmed C-1 location of the trans-p-
coumaroyl moiety while the trans-caffeoyl moiety was assigned at C-3. This was 
achieved through the 3J-HMBC correlation of the proton H-3 (δH 5.24) with the trans-
caffeoyl carbonyl carbon C-9''. Meanwhile, carbons C-1 and C-3 were downfield 
shifted (∆δC +2.5 and +4.9) while carbons C-2 and C-4 were upfield shifted (∆δC +4.0 




Primary Screening of Virtual Binding Affinity at The c-Met Kinase Domain and 
Cell Free c-Met Inhibitory Activity Confirmation. The structures 1-10 were 
docked at the ATP-binding site of the highly resolved c-Met kinase domain crystal 
structure PDB 2WD1 using Schrödinger molecular modeling software package in 
extra-precision (XP) mode. The docking scores indicated the ability of only three 
compounds to fit within the ATP-binding site of c-Met kinase (Table 3). Compounds 
are ranked in decreasing order are: 9, 8, and 10 according to their docking scores.  
To avoid the possibility of hit attrition that may arise due to scoring functions 
inaccuracy, all compounds (1-10) were screened in a cell-free Z'-LYTE™ enzymatic 
assay using a single 5 µM dose of each compound (Table 3). This assay directly 
measures the in vitro ability of tested compounds to inhibit c-Met phosphorylation 
(activation) of the purified kinase domain of c-Met, that was in vitro phosphorylated 
to achieve the highest level of intrinsic kinase activity. The Z'-LYTE assay results 
typically matched the docking data and confirmed the in silico activity of the three 
hits 8-10 (Table 3). Compound 9 was the most active in the primary screening stage 
showing around 80% c-Met phosphorylation inhibition, followed by 8 with 56.7% 
inhibition, and finally compound 10 with 38.8 % inhibition at 5 µM dose (Table 3). 
Secondary Screening and Assessment of Structural Determinants of The c-Met 
Inhibitory Activity. To validate the promising activity obtained in the primary 
screening, the inhibitory effects of various doses of hits 8-10 against the purified c-
Met kinase domain have been re-investigated using the cell-free Z'-LYTE™ 
enzymatic assay (Figure 2). The extra-virgin olive oil phenolic secoiridoid S (-)-
oleocanthal, with defined c-Met inhibitory activity,13 was used as a standard positive 
control at a 5 µM dose. As expected, compound 9 was the most active; with c-Met 
phosphorylation inhibitory IC50 value of 2.5 µM, followed by 8 (IC50 6.9 µM), and 
finally 10 (IC50 12.7 µM, Figure 2).  
To identify the structural basis for the c-Met binding affinity difference among 
8-10, docking simulation studies have been carried out at the c-Met crystal structure 
PDB 2WD1 (Figure 3). Interestingly, this docking study justified the potency of 9 
over compounds 8 and 10 in the cell-free assay. The docking study showed a dramatic 
difference in the binding mode of 8 compared to 9 and 10 (Figure 3). Due to its 
bulkiness, compound 8 showed a partial fitting with its trans-p-methoxycinnamate 
moiety protruding outside the c-Met kinase pocket and forming a hydrogen bond via 
its p-methoxy with Lys1232 at the tip of the activation loop (Figure 3). In addition, 
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compound 8 showed three additional hydrogen bonding interactions with Ile1084, 
Arg1208, and Asn1209 at the c-Met kinase domain. It can be clearly seen that the 
buried part of 8 within the pocket adopted an extended conformation compared to the 
U-shaped conformation observed in compounds 9 and 10 (Figure 3B). This 
observation could suggest that compound 8 might act as a class-II inhibitor, unlike 
compounds 9 and 10, which typically represent class-I c-Met inhibitors.10-12 Despite 
showing more hydrogen bonding interactions than 9, compound 8 lacked the critical 
interactions with Met1160 and Pro1158 at the hinge region of the c-Met kinase. Such 
interactions are well-known to confer potency for any c-Met inhibitor hit.11,12 The 
lack of these interactions at the hinge region, along with the incomplete fitting of 8 
within the c-Met kinase pocket could justify why 9 was more potent than 8 in the cell-
free assay. On the other hand, compounds 9 and 10 showed complete fitting within 
the c-Met kinase pocket compared to compound 8 (Figure 3B). Both compounds 
showed two hydrogen bonding interactions with Ile1084 at one of the hydrophobic 
subpockets and Asn1167 near the activation loop of the c-Met kinase. However; only 
compound 9 was able to satisfy the critical hydrogen bonding interaction with 
Met1160 at the hinge region via the carbonyl group of its trans-p-coumaroyl moiety. 
Compound 9 binding pose at the c-Met kinase domain. The c-Met's ATP binding 
site includes: (1) Hinge region: Met1160 and Pro1158.11,12 Interaction at this site is 
highly characteristic for all compounds targeting the ATP binding site in kinase 
domains; (2) Central hydrophobic region; (3) Two smaller hydrophobic subpockets; 
and (4) c-Met activation loop (Asp1222-Lys1245).11,12  The good binding affinity for 
any c-Met inhibitor hit is hypothesized to be through interactions with at least one of 
Asp1222, Phe1223, or Tyr1230 at the activation loop and either Pro1158 or Met1160 
at the hinge region, along with a good fitting within one or more of the hydrophobic 
regions.11,12 
The binding mode of 9 at the c-Met's ATP binding pocket was studied via 
docking studies using different c-Met crystal structures, in addition to the previously 
mentioned 2WD1, to minimize false positive results due to conformational variations. 
Two highly resolved c-Met kinase domain crystal structures PDB codes 3CD8 and 
4XYF were used to investigate the possible binding modes of 9 within the catalytic 
domain of the non-phosphorylated c-Met using Schrödinger software (Figure 4). 
In all crystal structures, 9 assumed a perfect U-shaped binding mode at the c-
Met kinase domain with ideal wrapping around Met1211, which was the typical 
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conformation of class-I c-Met inhibitors. Consistent with the results obtained in 
2WD1 crystal structure, the visualization of the docked pose of 9 in 3CD8 and 4XYF 
emphasized its complete shape fitting at the ATP binding pocket of c-Met kinase 
domain. Two possible binding poses were noticed for 9, mainly due to the structural 
symmetry of the acylating ester parts around the sugar moiety. In crystal structure 
3CD8, the p-phenolic hydroxyl group of the caffeoyl moiety is forming a pair of 
bidentate HB interactions with the backbone of both Met1160 and Pro1158 in the 
hinge region. In contrast, the same hydroxyl group interacted with the side chain of 
Asp1231 in the activation loop’s DFG motif of crystal structure 4XYF. The m-
phenolic hydroxyl interacted with Arg1208 in crystal structure 4XYF, whilst lacking 
any interactions in crystal structure 3CD8. Instead, the carbonyl group of the trans-p-
caffeoyl moiety engaged in a hydrogen bonding interaction with the backbone NH of 
Arg1086 in crystal structure 3CD8. The trans-p-coumaroyl moiety of 9 interacted via 
its carbonyl group with the backbone NH of Met1160 and extended to form 
hydrophobic interactions via its phenyl ring with Ile1084, Tyr1159, and Ala1221 at 
one of the hydrophobic subpockets in crystal structure 4XYF. In the lipophilic back 
pocket of the 3CD8’s activation loop, the same aromatic ring is sandwiched between 
Met1211 and Tyr1230, forming a strong pi-pi stacking interaction with Tyr1230, thus 
hindering its autophosphorylation necessary for c-Met activation and stabilizing the 
inhibitory conformation of the activation loop. The sugar part tethered the two 
cinnamate moieties in 9 appeared not to contribute any binding role, yet it provided 
the proper U-shaped conformation necessary for proper alignment of 9 binding 
pharmacophores at the c-Met kinase domain and thus, satisfied the critical HB 
interactions with both the hinge region and the activation loop.  
To validate the docking results, the original ligand of each of the c-Met crystal 
structures 4XYF and 3CD8 was docked into it’s the ATP binding pocket by using the 
same parameters which have been used for docking 9 (Figure 4C). The bound 
conformation of the co-crystal ligand was generated with a good root mean square 
displacement (RMSD) of 0.2 Å, indicating the robustness of the docking protocols. 
Compound 9 almost overlaid the original co-crystallized ligand of each crystal 
structure, demonstrating the same critical interaction with the hinge region's Met1160. 
In addition, the original ligand engaged in a HB interaction with the backbone amide 
hydrogen of Asp1222 in addition to a pi-pi stacking interaction with Tyr1230, which 
were also satisfied by 9 in crystal structure 3CD8 (Figure 4C, upper panel). Despite 
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the fact that the sugar moiety in 9 adopted a slight different conformation compared to 
the linker present in each of the two original ligands, it was still able to provide the 
proper U-shaped conformation and properly align the 9 binding pharmacophores at 
the c-Met kinase domain in order to satisfy the critical HB interactions with both the 
hinge region and the activation loop (Figure 4C). Together, the docking studies 
showed the good fitting of 9 in the c-Met kinase. The binding mode of 9 within the 
catalytic c-Met domain is consistent with the kinase assay data, implying the potential 
of 9 as a promising c-Met inhibitory hit. 
Antiproliferative activity against Various Human Breast Cancer Cell Lines. 
Compounds 1-10 were screened using the MTT cell proliferation assay for ability to 
inhibit hepatocyte growth factor (HGF)-induced proliferation of the c-Met-expressing 
highly invasive MDA-MB-231 breast cancer cells at 10 and 40 µM of each compound 
(Table 4). HGF, scatter factor, is the natural ligand for the activation of the c-Met 
receptor tyrosine kinase.10-12 Interestingly, the results obtained in the MTT assay 
typically matched the docking and the cell-free findings. Compound 9 was the most 
active, at 10 and 40 µM, it inhibited 50% and 80% of the HGF-mediated cell 
proliferation of MDA-MB-231 cells, followed by 8 with 32% and 61% cytotoxicity 
and finally compound 10 with 28% and 49% cytotoxicity, respectively (Table 4). 
In an attempt to follow up this two-doses screening assay, the three active 
compounds 8-10 were tested at different doses against the same breast cancer MDA-
MB-231 cells to calculate an IC50 value for each compound using the MTT assay 
(Figure 5). (-)-Oleocanthal with defined antiproliferative activity was used as a 
standard positive control at 10 µM dose.13 Compound 9 was able to inhibit the HGF-
mediated cell proliferation in a dose-dependent manner, with an IC50 value of 13.3 
µM, followed by compound 8, with an IC50 value of 29.2 µM, and finally compound 
10, with an IC50 value of 38.6 µM (Figure 5).     
The antiproliferative effects of 8-10 were analyzed against additional key 
human breast cancer cell lines using the MTT assay. The cell lines were chosen to 
represent a wide range of breast cancer phenotypes. ERα, one of the most important 
targets in human breast cancer therapy, is expressed in MCF-7 and BT-474 cells, 
whereas MDA-MB-231 and MDA-MB-468 cells lack the expression of ERα. On the 
other hand, c-Met is expressed at higher levels in TNBC MDA-MB-231 and MDA-
MB-468 cells, and expressed at relatively lower levels in MCF-7 and BT-474 cells. 
Accordingly, the human breast cancer cell lines expressing c-Met, namely MDA-MB-
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468, MCF-7, and BT-474, in addition to the previously tested MBA-MD-231, were 
chosen to determine the antiproliferative activities of 8-10 (Figure 6). HGF was added 
to the media to induce cell proliferation via c-Met activation. (-)-Oleocanthal with 
defined antiproliferative activity was used as a standard positive control at 20 µM 
dose.  
Treatment with 9 caused a dose-dependent suppression of HGF-induced 
proliferation of the three cell lines (Figure 6). Consistent with biochemical data, 
compound 9 was more potent than 8 and 10 in all tested breast cancer cell lines. In 
addition, compound 9 was more active against the highly c-Met-expressing TNBC 
MDA-MB-231 and MDA-MB-468 cells, compared to the MCF-7 cell line, which has 
lower c-Met expression level. Compound 9 maintained antiproliferative potency 
against the HER2-c-Met expressing hormone-dependent luminal B BT-474 breast 
cancer cells. These results indicated that compound 9 significantly inhibited the HGF-
dependent growth across multiple c-Met-expressing breast cancer cell lines in a dose-
responsive manner as compared to their vehicle-treated control groups, supporting the 
hypothesis that c-Met inhibition can be the main molecular target of this unique 
natural product in breast cancer (Figures 2 and 3).  
Antimigratory Activity against The TNBC MDA-MB-231 Cells. In addition to cell 
proliferation, the c-Met/HGF signaling axis plays an important role in cell motility 
and migration. Therefore, the hits 8-10 active in the primary and secondary screening 
were further evaluated at different doses in the wound-healing scratch assay (WHA) 
using the highly metastatic TNBC MDA-MB-231 cells. HGF was added to the media 
as activating mitogen to induce cell migration via c-Met activation. S (-)-Oleocanthal 
with defined antimigratory activity was used as a standard positive control at 10 µM 
dose.13  Compound 9 showed impressive cell migration inhibitory activity and 
potently inhibited the HGF-induced cell migration in a dose-dependent manner with 
an IC50 value of 0.98 µM (Figure 7). Surprisingly, compound 10 was more active than 
compound 8 in the cell migration assay despite being less active than 8 in all previous 
assays, which may suggest another molecular target, in addition to the c-Met kinase, 
for its cell migration inhibitory capacity. The IC50 values for compounds 10 and 8 in 
WHA were 8.1 and 13.5 µM, respectively (Figure 7).  
In conclusion, this study shows the potential of the acylated iridoids and 
rhmnopyranoses represented by hits 8-10 as novel classes of c-Met kinase inhibitors 
appropriate for future optimizations to control c-Met-dependent breast cancer.   
11 
 
 EXPERIMENTAL SECTION 
NMR spectra were recorded at and 2D C 13 ,H1General Experimental Procedures. 
, using 4d-methanol in using TMS as internal standard 400 and 100 MHz, respectively,
Bruker Avancences, on ) as refere49.9= Cδ and 3.34= Hδthe residual solvent peak ( 
III 400 MHz with BBFO Smart Probe and Bruker 400 MHz AEON Nitrogen-Free 
Magnet (Bruker AG, Switzerland). Carbon multiplicities were determined using 
DEPT-Q experiments. The optical rotation values were determined using a Jasco P-
1020 polarimeter (Easton, MD, USA). The UV spectrum in methanol was obtained 
using a Shimadzu UV 2401PC spectrophotometer. The IR spectra were obtained 
using a Jasco, FT IR 300E infrared spectrophotometer. ESI-MS data were obtained 
using a Thermo Scientific LTQ/XL Orbitrap (Waltham, MA USA). Column 
chromatography was performed using silica gel 60 (63-200 µm, Fluka, Sigma-
Alderich, Germany); Polyamide-6 (50-160 µm, Sigma-Aldrich, Germany) and 
Sephadex LH-20 (Sigma-Aldrich, Germany). HPLC separations were conducted 
using an Agilent 1260 Infinity preparative pump (G1361A), Agilent 1260 Diode array 
detector VL (G1315 D), Agilent 1260 Infinity Thermostand column compartment 
(G1361 A) and Agilent 1260 Infinity preparative Autosampler (G2260A). YMC-Pack 
ODS-A A-324 column (10 i.d. × 300 mm, YMC, Kyoto, Japan).  
Plant Material. P. odorata leaves were collected from the Giza Zoo garden, Egypt, 
March to May 2015. P. odorata was kindly identified by Dr. Abd El-Halim A. 
Mohammed, Horticultural Research Institute, Department of Flora and 
Phytotaxonomy Researches, Dokki, Cairo, Egypt. A voucher specimen (2015-BuPD 
45) was deposited at Department of Pharmacognosy, Faculty of Pharmacy, Beni Suef 
University, Egypt.  
Extraction and Isolations. Air-dried P. odorata leaves powder (5 kg) was 
successively extracted by cold maceration using 70% ethanol, followed by 
successively extraction with n-hexane, dichloromethane, ethyl acetate and n-butanol. 
The ethyl acetate portion (8 g) was fractionated on polyamide, then on Sephadex LH-
20 column, and finally preparative TLC to obtain compounds 9-13 and 15 (10, 7, 16, 
8, 3, 130 mg, respectively). The n-butanol portion (25 g) was fractionated on 
polyamide, followed by a Si gel 60, Sephadex LH-20, HPLC, then preparative TLC to 
obtained compounds 1-8 and 14
 
(10, 8, 10, 9, 7, 7, 18, 13 and 8 mg, respectively). 
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Premnoside F (1). Pale yellow amorphous solid; 25D][α  +5.8 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 228 (4.7), 308 (4.0), 318 (4.5), 371(4.3) nm; IR υmax (KBr) 3422, 
2924, 1699, 1632, 1604, 1267, 1015, 835 cm-1; NMR data: see Table 1; HRESIMS 
m/z 801.2621 [M+H]+ (calced for C39H44O18, 801.2606). 
Premnoside H (2). Pale yellow amorphous solid; 25D][α  +7.2 (c 0.08, MeOH); UV 
(MeOH) λmax (log ε) 247 (2.7), 308 (3), 315 (3.5) nm; IR υmax (KBr) 3429, 2927, 1712, 
1354, 1073, 554 cm-1. NMR data: see Table 1; HRESIMS m/z 851.2758 
[M+Na]+(calced for C41H48O18, 851.2738). 
Premnoside I (3). Pale yellow amorphous solid; 25D][α  +3.9 (c 0.1, MeOH); UV 
(MeOH) λmax (log ε) 222 (4.2), 275 (2.0), 309 (2.3), 321(4.0) nm; IR υmax (KBr) 3431, 
2922, 1603, 1070 cm-1; NMR data: see Table 1; HRESIMS m/z 817.2553 [M+H]+ 
(calced for C39H44O19, 817.2555). 
1-O-trans-p-coumaroyl-2-O-trans-caffeoyl-α-L-rhamnopyranose (9). Pale yellow 
amorphous solid; 25D][α  +34.8 (c 0.04, MeOH); UV (MeOH) λmax (log ε) 218 (sh), 225 
(2.5), 372 (3.0) nm; IR υ
max
 (KBr) 3421, 1692, 1604, 1270, 1167 and 1056 cm-1; NMR 
data: see Table 2; HRESIMS m/z 473.1426 [M+H]+ (calced for C24H24O10, 473.1448). 
1-O-trans-p-coumaroyl-3-O-trans-caffeoyl-α-L-rhamnopyranose (10). Pale 
yellow amorphous solid; 25D][α  +34.4 (c 0.04, MeOH); UV (MeOH) λmax (log ε) 214 
(sh), 225 (2.5), 375 (3.0) nm; IR υ
max
 (KBr) 3421, 1692, 1604, 1275, 1167, 1056 cm-1; 
NMR data: see Table 2; HRESIMS m/z 473.1426 [M+H]+ (calced for C24H24O10, 
473.1448). 
Molecular Modeling Studies. The in silico experiments were carried out using the 
Schrödinger molecular modeling software package installed on an iMac 27-inch 
Z0PG workstation with a 3.5 GHz Quad-core Intel Core i7, Turbo Boost up to 3.9 
GHz, processor, and 16 GB RAM (Apple, Cupertino, CA, USA). 
The X-ray crystal structures of the c-Met tyrosine kinase domain PDB codes 
2WD1, 4XYF, and 3CD8 were retrieved from the Protein Data Bank. The Protein 
Preparation Wizard was implemented to prepare the kinase domain of c-Met 
protein.18,19 Each protein was reprocessed by assigning bond orders, adding 
hydrogens, creating disulfide bonds, and optimizing H-bonding networks using 
PROPKA (Jensen Research Group, Denmark). Finally, energy minimization with 
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RMSD value of 0.3°A was applied using an Optimized Potentials for Liquid 
Simulation (OPLS_2005, Schrödinger, New York, USA) force field. 
The chemical structure of each compound was sketched on the Maestro 9.3 
panel interface (Maestro, version 9.3, 2012, Schrödinger, USA). The Lig Prep 2.3 
module (Lig Prep, version 2.3, 2012, Schrödinger, USA) was implemented to 
generate the 3D structure and to search for different conformers. The OPLS 
(OPLS_2005, Schrödinger, USA) force field was applied to geometrically optimize 
each ligand structure and to compute partial atomic charges. Finally, 32 poses per 
ligand were generated with different steric features for subsequent docking studies.  
The prepared X-ray crystal structure of c-Met was used to generate receptor 
energy grids applying the default value of the protein atomic scale (1.0°A) within the 
cubic box centered on the co-crystallized ligand of c-Met crystal structure. 
Compounds were then docked using the Glide 5.8 module (Glide, version 5.8, 2012, 
Schrödinger, USA) in extra-precision (XP) mode.20 Modeling scores were generated 
using the Glide-Dock program’s empirical scoring functions. 
Biochemical Cell-Free Kinase Assay. The Z’-LYTE™ Kinase Assay-Tyr6 Peptide 
kit (Life Sciences) was used to assess the ability of in silico hits to inhibit the catalytic 
activity of c-Met kinase (Product# PV3143).21 Briefly, 20 µL/well reactions were set 
up in 96-well plates containing kinase buffer, 200 µM ATP, 4 µM Z’-LYTE™ Tyr6 
Peptide substrate, 2500 ng mL-1 c-Met kinase and tested compound as an inhibitor. 
After 1 h of incubation at rt, 10 µL development solution containing site-specific 
protease was added to each well. Incubation was continued for 1 h. The reaction was 
then stopped, and the fluorescent signal ratio of 445 nm (coumarin)/520 nm 
(fluorescein) was determined on a plate reader (BioTek FLx800™), which reflects the 
peptide substrate cleavage and kinase inhibitory activity in the reaction.21  
Cell Lines, Culture Conditions, and Cell viability Assessments. The human breast 
cancer cell lines were purchased from the ATCC (Manassas, VA). All cancer cell 
lines were maintained in RPMI-1640 (Gibco® by Life Technologies, Grand Island, 
NY) supplemented with 10% fetal bovine serum (FBS, Gemini Bio-Products); 100 
U/mL penicillin G, 100 µg/mL streptomycin and 2 mmol/L glutamine. Cells were 
subcultured upon attaining 80% confluency. All cells were maintained at 37°C in a 
humidified incubator under 5% CO2. A stock solution was prepared by dissolving 
each tested compound in sterilized DMSO at a concentration of 10 mM for all assays. 
Working solutions at their final concentrations for each assay were prepared in 
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appropriate culture medium immediately prior to use. The vehicle (DMSO) control 
was prepared by adding the maximum volume of DMSO, used in preparing test 
compounds, to the appropriate media type such that the final DMSO concentration 
was maintained as the same in all treatment groups within a given experiment and 
never exceeded 0.1%. (-)-Oleocanthal was used in all experiments as a positive 
control based on earlier studies.13,21   
Viable cell count was determined using the MTT colorimetric assay. The 
optical density of each sample was measured at 570 nm on a Synergy 2 microplate 
reader (BioTek, VT, USA). The number of cells per well was calculated against a 
standard curve prepared at the start of each experiment by plating various 
concentrations of cells (1,000-60,000 cells per well), as determined using a 
hemocytometer. 
Cell Proliferation Assay. Breast cancer cells, in exponential growth, were seeded at a 
density of 1×104 cells per well (6 wells/group) in 96-well culture plates and 
maintained in RPMI-1640 media supplemented with 10% FBS and allowed to adhere 
overnight at 37°C under 5% CO2 in a humidified incubator.22 The next day, cells were 
washed with phosphate buffer saline (PBS), divided into different treatment groups 
and then fed serum-free defined RPMI-1640 media containing HGF (40 ng/mL as a 
mitogen which induced maximum growth in the two cell lines after 48 h) and 
experimental treatments (containing designated concentrations of the tested 
compounds) or vehicle-treated control media and incubation resumed at 37°C under 
5% CO2 for 48 h. Control and treatment media were then removed, replaced with 
fresh media, and 50 µL fresh MTT solution (1 mg mL-1) was added to each well and 
plates were re-incubated for 4 h at 37 ºC. The color reaction was stopped by removing 
the media and adding 100 µL DMSO in each well to dissolve the formed formazan 
crystals. Incubation at 37°C was resumed for up to 20 minutes to ensure complete 
dissolution of crystals. Absorbance was determined at λ 570 nm using an ELISA plate 
microreader (BioTek, Winooski, VT, USA).21,23 The % cell survival was calculated as 
follows: % cell survival = (Cell No.treatment/Cell No.DMSO) x 100.  
Cell Migration Assay. MDA-MB-231 cells were plated in sterile 24-well plates and 
allowed to form a confluent monolayer per well overnight.13,21 Wounds were then 
inflicted in each cell monolayer using a sterile 200 µL pipette tip. The media were 
removed and cells were washed twice with PBS and once with fresh RPMI medium to 
remove cell debris. Test compound concentrations were prepared in fresh serum-free 
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defined media, containing 40 ng/mL HGF as a mitogen, and were added to wells in 
triplicate. Cells were incubated for 24 h after which, the medium was removed and 
cells were washed, fixed, and stained using Giemsa stain. Wound healing was 
visualized at 0 and 24 h by a Nikon ECLIPSE TE200-U microscope and digital 
images were captured using Nikon NIS Elements software (Nikon Instruments Inc., 
Melville, NY). The distance traveled by the cells was determined by measuring the 
wound width after 24 h. Percentages cell migration were calculated using the 
following formula: 
Percent cell migration =  [T0-Tt-Tdmso] X 100                                                                                                  
                                             T0-Tdmso 
Where, T0 is wound thickness at zero time, Tdmso is wound thickness in DMSO-treated 
control wells and Tt is wound thickness in treated wells.  
Statistical Analyses. All in vitro experiments were performed in triplicate. Pooled 
data are presented as the means ± standard error of mean (SEM) of at least three 
independent experiments. Differences among various treatment groups were 
determined by ANOVA followed by Dunnett’s test using PASW statistics® version 18 
(Quarry Bay, Hong Kong). A difference of p<0.05 was considered statistically 
significant compared to the vehicle-treated control group and indicated by * symbol. 
The IC50 values were determined using a non-linear regression curve fitting analysis 
using GraphPad Prism software version 6 (La Jolla, CA, USA). 
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Table 1. 13C and 1H NMR Data of Compounds 1-3.a 
 
Position 
              1            2            3 
Aglycone 1, CH 93.8 5.08,  brs   93.8  5.05,  brs   93.9 5.05,  brs   
 
3, CH 140.9 6.39, d (6) 140.9  6.40, d (6) 140.9 6.39, d (6) 
 
4, CH 102.1 5.08, brs (1H,) 102.1  5.13, brs 102.3 5.13, brs 
 
5, CH 35.9 2.46, m  35.9  2.46, m  35.9 2.46, m  
 
6, CH 82.4  4.02, dd (8, 1.6) 82.4  4.02, dd (1, 8) 82.4 4.02, dd (1, 8) 
 
7, CH 58.0 3.68, m  58.1  3.68, m  58.0 3.68, m  
 
8, qC 65.3  65.2   65.3  
 
9, CH 41.8 2.59, dd (1, 8) 41.8  2.59, dd (1, 8) 41.9 2.59, dd (1, 8) 
 
10, CH2 60.1 3.85, d (2) 
4.17, d (12) 
60.1  3.85, d (2) 
4.17, d (12) 
60.0 3.85, d (2) 
4.17, d (12) 
β-D-Gluc. 1', CH 98.3 4.80, d (8) 98.3  4.79, d (8) 98.3 4.79, d (8) 
 
2', CH 73.4 3.31, m  73.4  3.31, m  73.4 3.31, m 
 
3', CH 76.2 3.46, m  76.2 3.46, m 76.2 3.46, m 
 
4', CH 70.3 3.32, m 70.4  3.32, m 70.3 3.32, m 
 
5', CH 77.2 3.34, m 77.2  3.34, m 77.2 3.34, m 
 
6', CH2 61.5 3.67, d (2)  
3.93, d (8) 
61.5  3.67, d (2)  
3.93, d (8) 
61.5 3.67, d (2)  
3.93, d (8) 
α-L-Rhamn.  1'', CH 98.8 5.00, brs   98.8  5.00, brs   98.9 5.00, brs 
 
2'', CH 69.1 3.98, m  69.1  3.96, m   69.1 3.96, m 
 
3'', CH 72.8 5.18, brs   72.8  5.18, brs   72.9 5.18, brs   
 
4'', CH 74.0 5.11, brs   74.0  5.11, brs   73.9  5.11, brs   
 
5'', CH 69.0 3.83, m   68.9  3.83, m   69.0  3.83, m   
 
6'', CH3 16.7 1.33, d (6) 16.6  1.33, d (6) 16.6 1.28, d (6) 
trans-p-Coum.  1''', qC 126.0  127.0   125.7  
 
2'''/6''',CH 130.0 7.49, d (8) 129.8  7.59, d (8) 129.8 7.49, d (8) 
 
3'''/5''' CH 115.5 6.84, d (8) 114.1 6.98, d (8 Hz) 115.6 6.84, d (8) 
 
4''', qC 160.0  161.9   160.0  
 
7''', CH 146.0 7.67, d (16) 145.5  7.71, d (16) 145.5 7.61, d (16) 
 
8''', CH 114.0 6.40, d (16) 115.0  6.46 , d (16) 113.8 6.40, d (16) 
 
9''', qC 167.6  167.3   167.5  
 
10''', OCH3   54.5   3.84, s    
trans-p-Coum. 1'''', qC 125.8  126.9     
 
2''''/6'''' CH 129.9 7.49, d (8) 129.6  7.59, d (8)   
 
3''''/5''''CH 115.5 6.84, d (8) 114.1  6.98, d (8)   
 
4'''', qC 159.8  161.8     
 
7'''', CH 145.5 7.71, d (16) 145.0  7.79, d (16)   
 
8'''', CH 113.5 6.45, d (16) 114.4  6.50, d (16)    
 




10'''', OCH3   54.5 3.84, s    
trans-p-Caff.  1'''', qC     125.8  
 
2'''', CH     114.1 7.10, s  
 
3'''', C     148.2  
 
4'''', C     145.3  
 
5'''', CH     115.2 6.83, d (8) 
 
6'''', CH     121.7 6.98, d (8) 
 
7'''', CH     145.9 7.68, d (16) 
 
8'''', CH     113.9 6.46, d (16) 
 
9'''', C     167.7  
aIn CD3OD, 400 MHz for 1H, 100 MHz for 13C NMR, J in Hz, carbon multiplicities 
were determined by DEPT-Q experiments, qC = quaternary, CH = methine, CH2 = 
methylene, CH3 = methyl carbons. 
 
 
Table 2. 13C and 1H NMR Data of Compounds 9 and 10.a 
 Position 
            9      10 
α-L-Rhamn. 1, CH 91.9 5.19, brs  94.4 5.14, brs   
 2 , CH 73.7 5.19, s  69.7 4.09, m  
 3 , CH 69.1 4.11, m  74.0 5.24, d (9.8) 
 4 , CH 73.2 3.62, m  70.4 3.72, m  
 5 , CH 68.3 3.99 (1H, m) 68.1 3.94, m  
 6 , CH3 17.0 1.34, d (6) 17.0 1.33, d (6) 
trans-p-Coum. 1' , qC 125.9  126.0  
 2'/6', CH 130.1 7.39, d (8) 130.0 7.39, d (8) 
 3'/5' , CH 115.6 6.81, d (8) 115.6 6.81, d (8) 
 4' , qC 159.6  159.5  
 7' , CH 146.0 7.66, d (16) 146.0 7.66, d (16) 
 8' , CH 113.6 6.38, d (16) 113.6 6.38, d (16) 
 9' , qC 168.0  167.9  
trans-Caff.   1'' , qC 126.5  126.7  
 2'' , CH 114.2 7.08, s  114.2 7.08, s  
 3'' , qC 148.0  148.1  
 4'' , qC 145.1  145.1  
 5'' , CH 115.4 6.81, d (8) 115.4 6.81, d (8) 
 6'' , CH 122.1 6.91, d (8) 122.0 6.91, d (8) 
 
7'' , CH 145.7 7.57, d (16) 146.4 7.57, d (16) 
 
8'' , CH 114.0 6.31, d (16) 114.0 6.31, d (16) 
 
9''  , qC 168.0  167.8  
aIn CD3OD, 400 MHz for 1H, 100 MHz for 13C NMR, J in Hz, carbon multiplicities 
were determined by DEPT-Q experiments, qC = quaternary, CH = methine, CH2 = 
methylene, CH3 = methyl carbons. 
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Table 3. Virtual Binding Affinity at c-Met Kinase Domain and Cell-Free Percentage 
Z’-LYTE Assay c-Met Phosphorylation Inhibition at A Single 5 µM Dose of 
Compounds 1-10 using the kit.a  
Compound Docking Score 
% c-Met Inhibition using Cell-Free assay (5 µM 
dose) 
1 N/A 0 % 
2 N/A 0 % 
3 N/A 10.9 % 
4 N/A 0 % 
5 N/A 0 % 
6 N/A 0 % 
7 N/A 0 % 
8 -8.4 56.7 % 
9 -8.8 79.8 % 
10 -8.1 38.8 % 
aModeling scores were also generated for all compounds using the Glide-Dock 
program’s empirical scoring functions. c-Met crystal structure PDB code: 2WD1.  






Table 4. Antiproliferative Activity of Compounds 1-10 against The Human TNBC 
Cells MDA-MB-231 at 10 and 40 µM Screening Doses Using The MTT Assay.a  
Compound % Survival Inhibition 
10 µM 40 µM 
1 ND  26 
2 ND 17 
3 27 30 
4 ND 7 
5 ND 20 
6 10 13 
7 13 18 
8* 32 61.3 
9* 51.3 79.3 
10* 28.2 49.2 
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Figure 1. Selected HMBC ( ) and 1H-1H COSY ( ) correlations of 












































































































Figure 2. c-Met phosphorylation inhibition by various doses of the most active hits 8-10 using the Z’-
LYTE assay kit. Error bars indicate the SEM of N=3/dose. Oleocanthal was used as a positive control at 
5 µM.13 The IC50 values were included for activity comparison.  
 
 




 Figure 3. In silico binding mode of 8-10 at the ATP binding site of the c-Met kinase 
domain (PDB code: 2WD1). A. Important hydrogen bonding interactions shown in 
dotted yellow lines along with the corresponding amino acids. B. Surface fitting of 8-
10 at the c-Met kinase domain. The transparent protein surface, in aquamarine color, 
and the solid ligand surface, in yellow green color, are shown to emphasize the degree 
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Figure 4. In silico binding mode of 9 at the ATP binding site of the c-Met kinase 
domain of crystal structure 3CD8 and 4XYF. Upper panel (A and B); Important 
hydrogen bonding interactions shown in dotted yellow lines along with the 
corresponding amino acids at each c-Met crystal structure. Lower panel (A and B); 
the transparent protein surface, in aquamarine color, and the solid surface of 9, in 
yellow-green color, emphasize the shape fitting of 9 within the target pocket of the 
crystal structures 3CD8 and 4XYF, respectively. (C) The structure overlay for 9 
(green tube) with the original ligand conformation (grey thin tube) obtained from c-
Met crystal structure 3CD8 (upper panel) and 4XYF (lower panel) using docking 
simulations; important hydrogen bonding interactions are shown in dotted red lines 























































































Figure 5. Effect of various doses of compounds 8-10 on the viability of the highly metastatic MDA-
MB-231 breast cancer cells, after HGF stimulation, compared to DMSO as a vehicle control. Viable 
cell count was determined using the MTT assay. Error bars indicate the SEM of N = 3/dose. 
Oleocanthal was used as a positive control at 10 µM.13 The IC50 values were included for activity 
comparison. 
 


































































































































































































































































Figure 6. Effect of various doses of compounds 8-10 on the viability of (A) MDA-MB-468, (B) 
MCF7, and (C) BT-474 breast cancer cells after HGF stimulation, compared to DMSO as a vehicle 
control. Viable cell count was determined using the MTT assay. Error bars indicate the SEM of N = 
3/dose. Oleocanthal was used as a positive control at 20 µM.13 The IC50 values were included for 
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Figure 7. Antimigratory activity of compounds 8-10 against the human TNBC MDA-MB-231 
cells. Left panel; effects of various doses of 8-10 on the HGF-induced MDA-MB-231 cells 
migration in wound healing assay (WHA), compared to DMSO as a vehicle control. Error bars 
indicate the SEM of N = 3/dose. Oleocanthal was used as a positive control at 10 µM.13 The 
IC50 values were included for activity comparison. Right panel; photomicrographs showing the 
migration inhibitory activity of each compound against the MDA-MB-231 cells in WHA at 
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